Hemostemix Inc

NEW
FRA:2VF0 (Canada)  
€ 0.018 -0.0035 (-16.28%) Jul 8
At Loss
Market Cap:
€ 7.61M ($ 8.70M)
Enterprise V:
€ 9.65M ($ 11.03M)
Volume:
0
Avg Vol (2M):
0
Trade In:

Business Description

Description
Hemostemix Inc is a clinical-stage biotechnology company whose principal business is to develop, manufacture, and commercialize blood-derived stem cell therapies for medical conditions not adequately addressed by current treatments. Its product ACP-01 is derived from a patient's own blood and evaluated in clinical research for ischemic conditions, including Cardiovascular Ischemia, Peripheral Arterial Disease (PAD), Chronic Limb Threatening Ischemia (CLTI), and Vascular Dementia.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt
0.09
Equity-to-Asset
-12.88
Debt-to-Equity
-0.66
Debt-to-EBITDA
-0.94
Piotroski F-Score
N/A/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI
9.37
9-Day RSI
21.22
14-Day RSI
27.81
3-1 Month Momentum %
-50
6-1 Month Momentum %
-40.3
12-1 Month Momentum %
-65.52

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
0.24
Quick Ratio
0.24
Cash Ratio
0.18

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-37.1
Shareholder Yield %
-39.32

Profitability Rank

Name Current Vs Industry Vs History
ROA %
-442.51
ROIC %
-7809.66
Moat Score
3
Tariff Resilience Score
6

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT
-4.04
EV-to-EBITDA
-4.04
EV-to-FCF
-2.56
Earnings Yield (Greenblatt) %
-24.78
FCF Yield %
-46.24

Financials

FRA:2VF0's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Hemostemix Inc Executives

Details

GF Valueâ„¢

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €)
EPS (TTM) (€) -0.015
Beta 0.2206
3-Year Sharpe Ratio 0.35
3-Year Sortino Ratio 1.4
Volatility % 77.05
14-Day RSI 27.81
14-Day ATR (€) 0.000701
20-Day SMA (€) 0.021275
12-1 Month Momentum % -65.52
52-Week Range (€) 0.018 - 0.0565
Shares Outstanding (Mil) 205

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Hemostemix Inc Filings

Filing Date Document Date Form
No Filing Data

Hemostemix Inc Stock Events

Financials Calendars
Event Date Price (€)
No Event Data

Hemostemix Inc Frequently Asked Questions

What is Hemostemix Inc(FRA:2VF0)'s stock price today?
The current price of FRA:2VF0 is €0.02. The 52 week high of FRA:2VF0 is €0.06 and 52 week low is €0.02.
When is next earnings date of Hemostemix Inc(FRA:2VF0)?
The next earnings date of Hemostemix Inc(FRA:2VF0) is .
Does Hemostemix Inc(FRA:2VF0) pay dividends? If so, how much?
Hemostemix Inc(FRA:2VF0) does not pay dividend.

Press Release

Subject Date
No Press Release

Articles on Hemostemix Inc

No articles.